文献速递乳腺癌放疗

保乳术后10次全乳放疗前瞻性II期试验

A prospective phase II trial of 10-fraction whole-breast radiotherapy following breast-conserving surgery.
PubMed 文献 · Clin Transl Radiat Oncol · 2026-03-26

该单臂前瞻性II期试验纳入64例早期乳腺癌患者,评估保乳术后10次全乳放疗(37 Gy/10次,序贯瘤床补量7.4 Gy/2次)的安全性与耐受性。主要终点≥2级急性放射性皮炎发生率为17.2%,无≥3级事件,全部在3个月内恢复至0-1级;患者报告的美容与乳腺症状评分在放疗后2周短暂恶化后恢复,功能与总体生活质量无显著下降。结论认为该10次方案可接受,可作为辅助乳腺放疗的实用替代选择。

要点

  • ≥2级急性放射性皮炎发生率为17.2%,无≥3级事件。
  • 58例(90.6%)接受瘤床补量,全部患者完成放疗无中断。
  • 美容与乳腺症状评分2周时短暂恶化后恢复,生活质量无显著下降。

核心结论

  • 保乳术后10次全乳放疗方案可接受,支持其作为辅助乳腺放疗的实用替代选择。

研究设计与样本

  • 单臂、前瞻性II期试验,于2023年11月至2025年3月在北京大学肿瘤医院纳入64例早期乳腺癌患者。

主要发现

  • 全部患者完成放疗无中断,58例(90.6%)接受瘤床补量。
  • ≥2级急性放射性皮炎发生率为17.2%,无≥3级事件,所有反应在3个月内恢复至0-1级。
  • 11例2级皮炎中,最常受累部位为乳头乳晕复合体(6例,54.5%)。
  • 患者报告的美容与乳腺症状评分在放疗后2周短暂恶化,此后恢复;功能或总体生活质量领域无显著下降。
  • 探索性分析提示既往化疗和较低基线CD4+ T细胞计数与≥2级皮炎风险较高相关。

关键数值与推荐

  • 全乳IMRT处方剂量37 Gy/10次,序贯瘤床补量7.4 Gy/2次(根据临床指征)。
  • 主要终点为≥2级急性放射性皮炎发生率;次要终点包括患者报告结局、美容评估、肿瘤学结局和探索性免疫分析。

临床怎么用

  • 该10次全乳放疗方案可作为保乳术后辅助放疗的实用替代选择,需关注乳头乳晕复合体皮炎及既往化疗、低基线CD4+ T细胞计数者的皮炎风险。

局限性

  • 单臂II期设计,样本量64例,随访时间有限,结论需更大样本及长期随访验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Moderate hypofractionation is established as the standard of care for adjuvant whole-breast radiotherapy after breast-conserving surgery. Ultra-hypofractionated regimens further shorten treatment but have raised concerns about toxicity and cosmetic outcomes. In younger Asian patients frequently requiring a boost, we evaluated a 10-fraction whole-breast radiotherapy schedule as a practical and tolerable choice. METHODS: This single-arm, prospective phase II trial enrolled 64 patients with early-stage breast cancer at Peking University Cancer Hospital between November 2023 and March 2025. All patients received intensity-modulated radiotherapy (IMRT) with a prescribed dose of 37 Gy in 10 fractions, followed by a sequential tumor-bed boost of 7.4 Gy in 2 fractions according to clinical indications. The primary endpoint was the incidence of grade ≥2 acute radiation dermatitis; secondary endpoints included patient-reported outcomes, cosmetic assessment, oncologic outcomes and exploratory immune profiling. Clinical Trial registration: ChiCTR2300075391. RESULTS: All patients completed radiotherapy without interruption. Tumor-bed boost was delivered to 58 patients (90.6%). Grade 2 acute dermatitis was observed in 17.2% of patients, with no grade ≥3 events, and all reactions resolved to grade 0-1 within three months. Among the 11 cases with grade 2 dermatitis, the most frequently affected site was the nipple-areola complex (6 cases, 54.5%). Patient-reported cosmetic and breast symptom scores transiently worsened at two weeks after radiotherapy but recovered thereafter. No significant decline occurred in functional or global quality-of-life domains. Exploratory analyses suggested that prior chemotherapy and lower baseline CD4+ T-cell counts were associated with a higher risk of grade ≥2 dermatitis. CONCLUSION: This 10-fraction whole-breast radiotherapy regimen was acceptable. These findings support this regimen as a practical alternative for adjuvant breast radiotherapy.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Xiang Y, Tie J, Zhang S, et al. A prospective phase II trial of 10-fraction whole-breast radiotherapy following breast-conserving surgery. Clin Transl Radiat Oncol. 2026. PMID: 41953587. doi:10.1016/j.ctro.2026.101149

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。